These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 10221740)

  • 1. Intent-to-treat analysis for longitudinal clinical trials: coping with the challenge of missing values.
    Mazumdar S; Liu KS; Houck PR; Reynolds CF
    J Psychiatr Res; 1999; 33(2):87-95. PubMed ID: 10221740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intent-to-treat analysis for longitudinal studies with drop-outs.
    Little R; Yau L
    Biometrics; 1996 Dec; 52(4):1324-33. PubMed ID: 8962456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling drop-outs in amyotrophic lateral sclerosis.
    Messina P; Beghi E
    Contemp Clin Trials; 2012 Jan; 33(1):218-22. PubMed ID: 21996525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A structured framework for assessing sensitivity to missing data assumptions in longitudinal clinical trials.
    Mallinckrodt CH; Lin Q; Molenberghs M
    Pharm Stat; 2013; 12(1):1-6. PubMed ID: 23193075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allowing for uncertainty due to missing and LOCF imputed outcomes in meta-analysis.
    Mavridis D; Salanti G; Furukawa TA; Cipriani A; Chaimani A; White IR
    Stat Med; 2019 Feb; 38(5):720-737. PubMed ID: 30347460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
    Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
    J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design considerations for handling dropouts in anti-depressant drug trials.
    Zhong J; Khin NA; Yang P
    Contemp Clin Trials; 2018 Feb; 65():69-75. PubMed ID: 29223579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Missing data imputation in two phase III trials treating HIV1 infection.
    Huson LW; Chung J; Salgo M
    J Biopharm Stat; 2007; 17(1):159-72. PubMed ID: 17219761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Partial imputation approach to analysis of repeated measurements with dependent drop-outs.
    Wei L; Shih WJ
    Stat Med; 2001 Apr; 20(8):1197-214. PubMed ID: 11304736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Augmentation Strategies in Major Depression.
    Martiny K
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early drop-outs, late drop-outs and completers: differences in the continuation phase of a clinical trial.
    Sonawalla SB; Farabaugh AH; Leslie VM; Pava JA; Matthews JD; Fava M
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Dec; 26(7-8):1415-9. PubMed ID: 12502032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ECNP consensus meeting. Bipolar depression. Nice, March 2007.
    Goodwin GM; Anderson I; Arango C; Bowden CL; Henry C; Mitchell PB; Nolen WA; Vieta E; Wittchen HU
    Eur Neuropsychopharmacol; 2008 Jul; 18(7):535-49. PubMed ID: 18501566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Marginal analysis of incomplete longitudinal binary data: a cautionary note on LOCF imputation.
    Cook RJ; Zeng L; Yi GY
    Biometrics; 2004 Sep; 60(3):820-8. PubMed ID: 15339307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.
    Hellerstein DJ; Stewart JW; McGrath PJ; Deliyannides DA; Batchelder ST; Black SR; Withers A; O'Shea D; Chen Y
    J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Missing data handling in chronic pain trials.
    Kim Y
    J Biopharm Stat; 2011 Mar; 21(2):311-25. PubMed ID: 21391004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Last-observation-carried-forward imputation method in clinical efficacy trials: review of 352 antidepressant studies.
    Woolley SB; Cardoni AA; Goethe JW
    Pharmacotherapy; 2009 Dec; 29(12):1408-16. PubMed ID: 19947800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors that influence the outcome of placebo-controlled antidepressant clinical trials.
    Niklson IA; Reimitz PE; Sennef C
    Psychopharmacol Bull; 1997; 33(1):41-51. PubMed ID: 9133750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accounting for dropout bias using mixed-effects models.
    Mallinckrodt CH; Clark WS; David SR
    J Biopharm Stat; 2001; 11(1-2):9-21. PubMed ID: 11459446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statistical analysis of longitudinal psychiatric data with dropouts.
    Mazumdar S; Tang G; Houck PR; Dew MA; Begley AE; Scott J; Mulsant BH; Reynolds CF
    J Psychiatr Res; 2007 Dec; 41(12):1032-41. PubMed ID: 17092516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.